Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study.
Patel A, Goodman SG, Tan M, Suskin N, McKelvie R, Mathew AL, Lutchmedial S, Dehghani P, Lavoie AJ, Huynh T, Lavi S, Philipp R, Khan R, Yan AT, Radhakrishnan S, Sedlak T, Brunner N, Kim HH, Cieza T, Kassam S, Fordyce CB, Heffernan M, Jedrzkiewicz S, Madan M, Ahmed S, Barry C, Dery JP, Bagai A; Canadian ACS Reflective II Investigators.
Patel A, et al. Among authors: philipp r.
Clin Cardiol. 2021 Jun;44(6):839-847. doi: 10.1002/clc.23618. Epub 2021 May 13.
Clin Cardiol. 2021.
PMID: 33982795
Free PMC article.